Ori A631
Alternative Names: Ori®A631Latest Information Update: 03 Aug 2022
At a glance
- Originator OriCell Therapeutics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action 5-nucleotidase inhibitors; Antibody-dependent cell cytotoxicity; CD39 antigen inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Solid tumours
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 13 Jul 2022 Ori A631 is available for licensing as of 13 Jul 2022. https://www.oricell.com/en/Contact/
- 06 Jul 2022 Preclinical trials in Solid tumours in China (Parenteral) (OriCell Therapeutics pipeline, July 2022)